0 Yorumlar
0 hisse senetleri
2K Views
0 önizleme
Site içinde arama yapın
Yeni insanlarla keşfedin, yeni bağlantılar oluşturmak ve yeni arkadaşlar edinmek
-
Please log in to like, share and comment!
-
CNS Therapeutics Market to Reach USD 243.6 Billion by 2033, Growing at 6.6% CAGRMarket Overview The global CNS therapeutics market size was valued at USD 137.04 Billion in 2024 and is expected to grow from USD 146.09 Billion in 2025 to reach USD 243.6 Billion by 2033, exhibiting a CAGR of 6.6% during the forecast period (2025–2033). The global CNS Therapeutics market continues to evolve rapidly, driven by shifting consumer trends,...0 Yorumlar 0 hisse senetleri 2K Views 0 önizleme
-
Hepatitis B Therapeutics Market to Reach $5.94 Billion by 2033 — Growing at 3.65% CAGRMarket Overview The global hepatitis b therapeutics market size was valued at USD 4.3 billion in 2024 and is projected to reach from USD 4.46 billion in 2025 to USD 5.94 billion by 2033, growing at a CAGR of 3.65% during the forecast period (2025-2033). The global Hepatitis B Therapeutics market continues to evolve rapidly, driven...0 Yorumlar 0 hisse senetleri 1K Views 0 önizleme
-
How Chronic Disease Growth Is Increasing Need for Hospital Infection TherapeuticsThe global hospital infection therapeutics market continues to grow as hospitals and healthcare facilities face rising cases of healthcare-associated infections (HAIs). These infections—ranging from bloodstream infections and surgical site infections to pneumonia and urinary tract infections—pose serious risks to patient safety and hospital operations. Hospital infection...0 Yorumlar 0 hisse senetleri 576 Views 0 önizleme
-
Multiple Sclerosis Drugs Market to Reach $36.6 Billion by 2033, Growing at 3.7% CAGRMarket Overview The global multiple sclerosis drugs market size was valued at USD 26.39 billion in 2024 and is projected to reach from USD 27.37 billion in 2025 to USD 36.6 billion by 2033, growing at a CAGR of 3.7% during the forecast period (2025-2033). The global Multiple Sclerosis Drugs market is witnessing swift transformation driven by new consumer...0 Yorumlar 0 hisse senetleri 1K Views 0 önizleme